Assessment of survival and cardiotoxicity of adjuvant trastuzumab among HER2 breast cancer patients in an oncology centre in Malaysia / Harissa H Hasbullah … [et al.]
Adjuvant trastuzumab has been used in human epidermal growth factor-2 (HER2) breast cancer to improve survival but with concern of cardiotoxicity. Our study is the first to review efficacy and toxicity of adjuvant trastuzumab in Malaysia. Methods: This is a retrospective cohort study on HER2 non met...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universiti Teknologi MARA Cawangan Selangor
2018
|
| Subjects: | |
| Online Access: | https://ir.uitm.edu.my/id/eprint/30061/ |
| _version_ | 1848807401839394816 |
|---|---|
| author | Hasbullah, Harissa H Bustamam, Anita Tho, Lye Munn Phua, Vincent |
| author_facet | Hasbullah, Harissa H Bustamam, Anita Tho, Lye Munn Phua, Vincent |
| author_sort | Hasbullah, Harissa H |
| building | UiTM Institutional Repository |
| collection | Online Access |
| description | Adjuvant trastuzumab has been used in human epidermal growth factor-2 (HER2) breast cancer to improve survival but with concern of cardiotoxicity. Our study is the first to review efficacy and toxicity of adjuvant trastuzumab in Malaysia. Methods: This is a retrospective cohort study on HER2 non metastatic breast cancer patients in University Malaya Medical Centre diagnosed between October 2006 and May 2011. Two cohorts were created based on whether or not they received adjuvant trastuzumab. Disease free survival (DFS) and overall survival (OS) for both groups were estimated using Kaplan Meier method and compared using Log rank test. Cox proportional hazards regression models analysed for potential covariates of age, tumour size and grade, node and estrogen receptor (ER) status. Trastuzumab cardiotoxicity was defined as left ventricular systolic dysfunction or heart failure with or without symptoms and graded using Common Terminology Criteria for Adverse Events (CTCAE 4.0). Results: 170 HER2 non metastatic breast cancer patients were identified. Thirty-three received trastuzumab and 136 did not. Median age was 53.4 ± 10.3 years old. Significantly more ER negative patients received trastuzumab. Four years DFS in ‘trastuzumab’ versus ‘no trastuzumab’ cohort was 90.9% vs 74.5% (p = 0.027). Four years OS was 91% vs 84.7% (p = 0.30) respectively. Majority tolerated trastuzumab with no toxicity. Five patients (15.2%) experienced cardiotoxicity (all grade I).Conclusions: Adjuvant trastuzumab significantly improved DFS in HER2 breast cancer. Treatment was well tolerated. With this we propose the justification for adjuvant trastuzumab in HER2 breast cancer in our population. |
| first_indexed | 2025-11-14T22:42:15Z |
| format | Article |
| id | uitm-30061 |
| institution | Universiti Teknologi MARA |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-14T22:42:15Z |
| publishDate | 2018 |
| publisher | Universiti Teknologi MARA Cawangan Selangor |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | uitm-300612020-04-21T13:24:54Z https://ir.uitm.edu.my/id/eprint/30061/ Assessment of survival and cardiotoxicity of adjuvant trastuzumab among HER2 breast cancer patients in an oncology centre in Malaysia / Harissa H Hasbullah … [et al.] jchs Hasbullah, Harissa H Bustamam, Anita Tho, Lye Munn Phua, Vincent RC Internal Medicine Neoplasms. Tumors. Oncology Cancer Adjuvant trastuzumab has been used in human epidermal growth factor-2 (HER2) breast cancer to improve survival but with concern of cardiotoxicity. Our study is the first to review efficacy and toxicity of adjuvant trastuzumab in Malaysia. Methods: This is a retrospective cohort study on HER2 non metastatic breast cancer patients in University Malaya Medical Centre diagnosed between October 2006 and May 2011. Two cohorts were created based on whether or not they received adjuvant trastuzumab. Disease free survival (DFS) and overall survival (OS) for both groups were estimated using Kaplan Meier method and compared using Log rank test. Cox proportional hazards regression models analysed for potential covariates of age, tumour size and grade, node and estrogen receptor (ER) status. Trastuzumab cardiotoxicity was defined as left ventricular systolic dysfunction or heart failure with or without symptoms and graded using Common Terminology Criteria for Adverse Events (CTCAE 4.0). Results: 170 HER2 non metastatic breast cancer patients were identified. Thirty-three received trastuzumab and 136 did not. Median age was 53.4 ± 10.3 years old. Significantly more ER negative patients received trastuzumab. Four years DFS in ‘trastuzumab’ versus ‘no trastuzumab’ cohort was 90.9% vs 74.5% (p = 0.027). Four years OS was 91% vs 84.7% (p = 0.30) respectively. Majority tolerated trastuzumab with no toxicity. Five patients (15.2%) experienced cardiotoxicity (all grade I).Conclusions: Adjuvant trastuzumab significantly improved DFS in HER2 breast cancer. Treatment was well tolerated. With this we propose the justification for adjuvant trastuzumab in HER2 breast cancer in our population. Universiti Teknologi MARA Cawangan Selangor 2018-06 Article PeerReviewed text en https://ir.uitm.edu.my/id/eprint/30061/1/AJ_HARISSA%20H.%20ABDULLAH%20JCHC%20B%2018.pdf Hasbullah, Harissa H and Bustamam, Anita and Tho, Lye Munn and Phua, Vincent (2018) Assessment of survival and cardiotoxicity of adjuvant trastuzumab among HER2 breast cancer patients in an oncology centre in Malaysia / Harissa H Hasbullah … [et al.]. (2018) Journal of Clinical and Health Sciences <https://ir.uitm.edu.my/view/publication/Journal_of_Clinical_and_Health_Sciences.html>, 3 (1). pp. 1-10. ISSN 0127-984X https://jchs-medicine.uitm.edu.my/index.php |
| spellingShingle | RC Internal Medicine Neoplasms. Tumors. Oncology Cancer Hasbullah, Harissa H Bustamam, Anita Tho, Lye Munn Phua, Vincent Assessment of survival and cardiotoxicity of adjuvant trastuzumab among HER2 breast cancer patients in an oncology centre in Malaysia / Harissa H Hasbullah … [et al.] |
| title | Assessment of survival and cardiotoxicity of adjuvant trastuzumab among HER2 breast cancer patients in an oncology centre in Malaysia / Harissa H Hasbullah … [et al.] |
| title_full | Assessment of survival and cardiotoxicity of adjuvant trastuzumab among HER2 breast cancer patients in an oncology centre in Malaysia / Harissa H Hasbullah … [et al.] |
| title_fullStr | Assessment of survival and cardiotoxicity of adjuvant trastuzumab among HER2 breast cancer patients in an oncology centre in Malaysia / Harissa H Hasbullah … [et al.] |
| title_full_unstemmed | Assessment of survival and cardiotoxicity of adjuvant trastuzumab among HER2 breast cancer patients in an oncology centre in Malaysia / Harissa H Hasbullah … [et al.] |
| title_short | Assessment of survival and cardiotoxicity of adjuvant trastuzumab among HER2 breast cancer patients in an oncology centre in Malaysia / Harissa H Hasbullah … [et al.] |
| title_sort | assessment of survival and cardiotoxicity of adjuvant trastuzumab among her2 breast cancer patients in an oncology centre in malaysia / harissa h hasbullah … [et al.] |
| topic | RC Internal Medicine Neoplasms. Tumors. Oncology Cancer |
| url | https://ir.uitm.edu.my/id/eprint/30061/ https://ir.uitm.edu.my/id/eprint/30061/ |